The problem of accessibility for socially significant goods for the population, among which the most important place occupy medicines in Ukraine, is very acute today. In this regard, the need for specific state interference through regulatory processes becomes relevant. One of the priority directions for increasing the availability of medicines is the Government of Ukraine has recognized reimbursement. The mechanism of full or partial payment of the cost of medicines used to counteract most socially significant diseases. One of these diseases is bronchial asthma (BA), since it affects all age groups of the population, and with ineffective control of the disease, the quality of life of patients is significantly reduced. The aim of the work is to study the range of medicines for the treatment of BA, included in the Government program «Accessible medicines» for the period 2017–2019 years. From April 1, 2017 to July 1, 2019, the Ministry of Health of Ukraine issued five orders, which approved the Register of medicines, the cost of which is subject to reimbursement. In the study analyzed all editions of the Register and found that with each update, the number of trade names (TN) of the medicines increased: for the treatment of cardiovascular diseases – by 56%, diabetes – by 92%, and BA – by 133%. During the 2017–2019 years, the number of international non-proprietary names (INNs) for the treatment of BA also increased: 3 times Beclomethasone, Budesonide 3.5 times, and Salbutamol is almost 2 times. Also, found that 87% of TN are imported and only 13% – domestic. Total of medicines for the treatment of asthma, the value of which is refundable imports 6 countries, the main segment of which is formed by Spain (31%) and Sweden (23%). The analysis of the size and amount of rejection and the amount of the surcharge for packaging allows us to establish that the percentage of medicines without an additional payment is approximately up to 50%. At 75% of the medicines for the treatment of BA, the amount of packing surcharge with each edition of the Register of medicines subject to reimbursement was increased by 2 medicines (Beckhazon-eco 100 mcg/dose and 250 mcg/dose) and 1 medicine (Budesonide-inteli 200 mcg/dose) – decreased 1 medicine (Budesonide-inteli 200 mcg/dose) subject to partial compensation only once. The conducted studies allow us to conclude that there is a need to improve the assortment policy in order to provide the pharmaceutical market with the available and necessary domestic medicines, in accordance with the needs of the population and the standards for the treatment of BA.

The aim: To investigate the pharmacists level of readiness to provide assistance to pharmacy visitors on COVID-19 and ways to expand their social role in society during the pandemic. Materials and methods: Based on the analysis of the statistical data, sociological research and mathematical analysis, as well as generalization of the obtained results have been used in the work. The objects of the study were pharmaceutical workers of pharmacies. The survey was conducted in August 2021 via online survey of the target audience in professional groups. Results: The results of the survey of pharmaceutical workers indicate a high level of need (63.9% of respondents) for the continuous acquisition of relevant information on COVID-19. According to the results of the study, the growth of the social role of pharmacy specialists in combating coronavirus infection has been proved, which was supported by 86.2% of respondents in their daily activities. The possibility of introduction of 6 new functions to Ukrainian pharmacies has been considered. Conclusions: The practical significance of the obtained results is that together they create a scientific and methodological basis for improving the process of pharmaceutical workers participation in combating coronavirus infection.

The availability of medicines the public is a problem with the most acute health care systems. Not only the issue of physical availability of medicines, their availability in pharmacies, but also the economic assistance of the population to purchase drugs is relevant. To overcome these problems, the Government has recognized the introduction of a reimbursement process in the pharmaceutical sector. The content of improving the quality and life expectancy of the population, with increasing physical and economic accessibility of drugs for the treatment of the most socially significant diseases, April 1, 2017 the Government introduced a reimbursement program «Available medicines». In the beginning there were spreads with cardiovascular disease, type II diabetes and bronchial asthma. From October 1, 2021, the program includes drugs for the treatment of diabetes mellitus, mental and behavioral disorders, epilepsy. The aim of the work is to study the dynamics of the range of drugs included in the government programs «Available medicines» for 2017–2022. The content analysis of 13 issues of Registers of medicines subject to reimbursement shows the updating and growth of the number of international non-proprietary names and in accordance with the trade names of drugs for the treatment of nosologies, which countries have recognized as the best. The nomenclature of medicines has been updated twice with international non-proprietary names and in almost 3 varieties – by trade names compared to the first issue, which is associated with both the expansion of names for the treatment of the disease, which were in programs since 2017 and the emergence of new nosology from 2021. On average, the share of drugs of domestic pharmaceutical companies is only 60%, which opens a significant prospect of import substitution, reduces drug prices under the government program «Available medicines» and, for example, increase the physical and economic availability of drugs. The conducted studies allow us to conclude that there is a need to improve the assortment policy of the government program «Available medicines» using the population of Ukraine available drugs in accordance with the needs of the population and the standards for the treatment socially significant diseases.

Національний медичний університет імені О. О. Богомольця Огляд ринку лікарських засобів, що застосовуються для лікування бронхіальної астми у дітей Мета: огляд асортименту лікарських засобів, що застосовуються для лікування бронхіальної астми у дітей, представлених на фармацевтичному ринку України. Матеріали та методи. Для досягнення поставленої мети нами був проведений аналіз лікарських засобів, що застосовуються для лікування бронхіальної астми у дітей, із використанням інформаційної бази зареєстрованих лікарських засобів, що представлена на офіційному сайті ДУ «Державний експертний центр» МОЗ України, інструкцій до медичного застосування лікарських засобів, Уніфікованого клінічного протоколу первинної, вторинної (спеціалізованої) медичної допомоги-бронхіальна астма у дітей. Дослідження виконано з використанням статистичного, логічного і графічного методів. Результати дослідження. Згідно з Уніфікованим клінічним протоколом первинної, вторинної (спеціалізованої) бронхіальної астми у дітей та Державним реєстром лікарських засобів України було сформовано досліджувану вибірку лікарських засобів. Проаналізовано цю групу лікарських засобів за асортиментом лікарських форм. Досліджено країни-виробники та фармацевтичні компанії, представлені на вітчизняному ринку лікарських засобів для лікування бронхіальної астми у дітей. Здійснено структуризацію цих препаратів за АТС-класифікацією. Висновки. Проведено дослідження асортименту лікарських засобів для лікування бронхіальної астми у дітей та виявлено найбільш розповсюджені лікарські форми. Встановлено частку вітчизняних виробників та країн-імпортерів досліджуваного сегмента ринку. Виходячи з результатів дослідження була встановлена необхідність розширення номенклатури вітчизняних лікарських засобів, що застосовуються для лікування бронхіальної астми у дітей. Ключові слова: аналіз фармацевтичного ринку; бронхіальна астма; виробники; лікарські форми; міжнародні непатентовані назви; асортимент лікарських засобів. I. A. Kostiuk The market review of drugs for treating asthma in children Aim. To make a review of the assortment of drugs presented at the pharmaceutical market of Ukraine to treat asthma in children. Materials and Methods. To achieve the goal the list of drugs for treating asthma in children was analyzed using the information database of the registered medicines presented at the official website of the State Enterprise "State Expert Center of the Ministry of Health of Ukraine", patient information leaflets, provisions of the Unified clinical protocol of the primary, secondary (specialized) care-Bronchial asthma in children. The study was conducted using statistical, logical and graphical methods. Results. According to the Unified clinical protocol of the primary, secondary (specialized) care-Bronchial asthma in children and the Ukrainian State Register of Drugs the sample of the drugs under research was formed. This group of drugs was analyzed according to the assortment of dosage forms. Manufacturing countries and pharmaceutical companies presented at the domestic ...

The article focuses on analysis of the main system types to deliver aerosol medication. They have their advantages and disadvantages and used in different age range patient. The main specific features of using different inhalers and medications have been determined. The algorithm to choose an inhaler type for children with bronchial asthma has been suggested which can be which can be insured by pharmacists to provide pharmaceutical care. The content analysis of the Instructions to use inhalation medications has been done. The need to enlarge the given information and to provide schematic addition of the inhalation procedure to the instruction has been defined.